TD Cowen Maintains Buy on GeneDx Hldgs, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Dan Brennan maintains a Buy rating on GeneDx Hldgs (NASDAQ:WGS) and raises the price target from $14 to $24, indicating a positive outlook on the company's stock.

April 30, 2024 | 3:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TD Cowen's analyst Dan Brennan reaffirms a Buy rating on GeneDx Hldgs and increases the price target to $24 from $14, showing strong confidence in the company's future performance.
The increase in price target by a reputable analyst like Dan Brennan from TD Cowen suggests a strong bullish sentiment towards GeneDx Hldgs. This is likely due to positive developments within the company or favorable market conditions affecting its business. Such a significant adjustment in the price target can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100